“First-Line Ipilimumab With Nivolumab Versus Immune Checkpoint Inhibitors With Tyrosine Kinase Inhibitors in Patients With Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma”. Journal of Kidney Cancer, vol. 12, no. 2, Apr. 2025, pp. 27-36, https://doi.org/10.15586/jkcvhl.v12i2.387.